Success Metrics

Clinical Success Rate
77.8%

Based on 7 completed trials

Completion Rate
78%(7/9)
Active Trials
0(0%)
Results Posted
86%(6 trials)
Terminated
2(22%)

Phase Distribution

Ph phase_1
1
11%
Ph phase_3
2
22%
Ph phase_2
1
11%
Ph phase_4
5
56%

Phase Distribution

1

Early Stage

1

Mid Stage

7

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
1(11.1%)
Phase 3Large-scale testing
2(22.2%)
Phase 4Post-market surveillance
5(55.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

77.8%

7 of 9 finished

Non-Completion Rate

22.2%

2 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(7)
Terminated(2)

Detailed Status

Completed7
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
77.8%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (11.1%)
Phase 21 (11.1%)
Phase 32 (22.2%)
Phase 45 (55.6%)

Trials by Status

terminated222%
completed778%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_3

A Study of YM178 in Subjects With Symptoms of Overactive Bladder

NCT01043666
terminatedphase_4

Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder

NCT01302938
completedphase_4

A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder

NCT00137397
completedphase_4

Effects Of Detrol LA On Memory And Cognition In Elderly Population

NCT00411437
completedphase_4

A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)

NCT02138747
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT01043666Phase 3

A Study of YM178 in Subjects With Symptoms of Overactive Bladder

Completed
NCT01302938Phase 4

Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder

Terminated
NCT00137397Phase 4

A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder

Completed
NCT00411437Phase 4

Effects Of Detrol LA On Memory And Cognition In Elderly Population

Completed
NCT02138747Phase 4

A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)

Completed
NCT01741454Phase 4

Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction

Completed
NCT01314872Phase 2

A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)

Completed
NCT01500382Phase 1

A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)

Terminated
NCT00611026Phase 3

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9